The VHL protein serves as the substrate recognition receptor for the Cullin 2 RING E3 ubiquitin ligase complex, forming the VCB complex together with Elongin B and Elongin C. This complex plays a crucial role in cellular hypoxia response and protein homeostasis maintenance. The VHL protein recognizes hydroxylated substrates and presents them to the E3 ligase complex for ubiquitination, leading to subsequent degradation of target proteins via the proteasome pathway. This mechanism makes the VCB complex an important tool in targeted protein degradation technologies. The TR-FRET VCB Complex Ligand Screening Kit can be used to quantitatively detect the binding activity of compounds to the VCB complex, providing a technical tool for ligand screening.
Targeted protein degradation technology utilizes the cell's inherent ubiquitin-proteasome system to achieve selective clearance of pathogenic proteins. Unlike traditional inhibition strategies, degradation technology can target proteins traditionally considered "undruggable," including transcription factors, scaffold proteins, and multimeric protein complexes. As one of the first E3 ligases used in PROTAC design, the discovery and optimization of ligands for the VHL complex have significantly advanced this field. TR-FRET technology can be applied to study conformational changes in the VCB complex upon compound binding and evaluate dynamic changes in ligand-receptor interactions under different conditions.
TR-FRET technology combines the principles of time-resolved fluorescence and fluorescence resonance energy transfer. Time-resolved fluorescence utilizes the long-lived fluorescence properties of lanthanide chelates to effectively eliminate short-lived background fluorescence interference. Fluorescence resonance energy transfer occurs when donor and acceptor fluorescent molecules are sufficiently close, generating specific signals through non-radiative energy transfer. In VCB complex ligand screening, donor-labeled VHL protein and acceptor-labeled ligands are co-incubated, and energy transfer occurs upon ligand binding to VHL. The addition of competitive compounds reduces signal intensity, reflecting the compound's competitive effect on ligand binding.
The TR-FRET VCB Complex Ligand Screening Kit is designed based on a competitive binding assay format. The kit includes labeled VHL protein, labeled high-affinity ligands, and optimized detection buffer. During detection, test compounds are mixed with kit components and incubated, and the inhibition rate of compound binding is calculated by measuring TR-FRET signal intensity. This method features homogeneity, no-wash steps, high sensitivity, and high throughput, making it suitable for large-scale compound screening. Compared to traditional ELISA methods, TR-FRET technology offers simpler operation, shorter detection time, and lower sample consumption, making it more suitable for early-stage drug discovery screening needs.
The TR-FRET VCB Complex Ligand Screening Kit has multifaceted application value in targeted protein degradation drug development. In the hit discovery phase, it can be used for high-throughput screening of small molecules binding to VHL protein to identify lead structures with development potential. During structure optimization, it can quantitatively compare the binding affinity of different compounds, providing data support for structure-activity relationship studies. In compound selectivity evaluation, it can assess selectivity between VHL and other E3 ligases. In PROTAC molecule design, it can evaluate the effectiveness of compounds as E3 ligase ligands, guiding PROTAC molecule design and optimization. The high-throughput nature of TR-FRET technology enables rapid screening of large compound libraries, accelerating the drug discovery process.
VHL-based PROTAC molecules consist of three parts: a target protein ligand, a linker, and a VHL ligand. These molecules can simultaneously bind the target protein and the VHL complex, inducing ubiquitination and degradation of the target protein. Numerous VHL-based PROTACs targeting disease-related proteins, including kinases, nuclear receptors, and epigenetic proteins, have been reported. These studies demonstrate that VHL-based degradation strategies can effectively reduce target protein levels, showing promising application prospects. The TR-FRET VCB Complex Ligand Screening Kit can be used to evaluate the binding activity of the VHL ligand portion in PROTAC molecules and validate the mechanism of action of degradation molecules.
With the rapid development of targeted protein degradation technology, the demand for efficient and specific E3 ligase ligands continues to grow. The application scope of the TR-FRET VCB Complex Ligand Screening Kit will expand further. Future directions include: developing selective ligands for VHL binding sites, exploring synergistic effects between the VHL complex and other E3 ligases, and applying TR-FRET technology to evaluate intracellular target protein degradation activity. As a quantitative detection tool for studying protein interactions, TR-FRET technology will continue to play a vital role in the field of targeted protein degradation, providing technical support for the discovery and optimization of novel degradation drugs.
Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed the "UniOne® TR-FRET Human VCB (VHL Complex) Binding Kit" (Catalog No.: UA086119), a high-performance analysis platform specifically designed for studying interactions between the VHL-EloB-EloC (VCB) complex and substrates or ligands. The VHL protein is a core component of the E3 ubiquitin ligase complex, playing a key role in hypoxia-inducible factor (HIF) degradation and tumor suppression, as well as serving as an important target in targeted protein degradation (PROTAC) technology. Based on time-resolved fluorescence resonance energy transfer (TR-FRET) technology, this kit enables precise and efficient evaluation of binding activity between human VCB complexes and ligands (or candidate compounds), providing a stable and reliable standardized solution for PROTAC technology development, anti-tumor drug screening, and novel drug discovery.
| Core Product Advantages | Detailed Parameters / Functional Description |
|---|---|
| High Purity and Complete Biological Activity | The kit's core components include high-purity, biologically active human VCB complex (VHL, EloB, and EloC ternary protein complex) and fluorescently labeled HIF-1α-derived peptide substrate (or ligand probe), validated through multi-dimensional quality control. The VCB complex maintains correct native conformation and intact substrate recognition function, accurately simulating the specific binding of VHL to hydroxylated proline substrates under physiological conditions, ensuring experimental data accuracy, reproducibility, and functional relevance. |
| Excellent Batch-to-Batch Consistency and Stability | Relying on an internationally leading protein expression platform and highly standardized production processes, combined with a stringent quality control system, the product exhibits excellent long-term stability and outstanding batch-to-batch consistency, providing solid and reliable quality assurance for long-term and continuous drug screening and mechanistic research. |
| Ready-to-Use Flexible Experimental Platform | Based on homogeneous TR-FRET technology, this kit adopts a simple "add-incubate-read" operation mode without tedious washing steps. Its optimized formulation system is compatible with multi-well plate (96/384-well) automation platforms, flexibly applicable to high-throughput screening of VHL ligands/molecular glue degraders, affinity determination of HIF-1α peptide analogs, competitive binding assays, and PROTAC molecule activity evaluation, among other research applications. |
| Complete Solution and Professional Support | We provide fully validated standard experimental protocols, typical dose-response curves, and detailed result interpretation guidelines to help you quickly establish stable and reproducible experimental workflows. Nanjing UA-Bio's professional technical team offers comprehensive technical consultation and support for research design, experimental optimization, and data analysis. |
Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug discovery. For detailed technical parameters, validation data, or specific application inquiries regarding the "UniOne® TR-FRET Human VCB (VHL Complex) Binding Kit" (Catalog No.: UA086119), please feel free to contact us.
